.Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01B_Antimetabolites.L01BC07_Azacitidine.Azacitidine_1

Information

Azacitidine is a nucleoside metabolic inhibitor with antineoplastic activity, primarily used in the treatment of myelodysplastic syndromes (MDS) and certain types of acute myeloid leukemia (AML). It acts by incorporation into DNA and RNA, resulting in cytotoxicity and inhibition of DNA methyltransferase. Azacitidine is approved for clinical use and is currently used in therapy.

Pharmacokinetics

Pharmacokinetic parameters reported for adult patients with myelodysplastic syndromes after subcutaneous administration of azacitidine.

References

1. Watts, JM, et al., & Cortes, JE (2023). Olutasidenib alone or with azacitidine in IDH1-mutated acute myeloid leukaemia and myelodysplastic syndrome: phase 1 results of a phase 1/2 trial. The Lancet. Haematology 10(1) e46–e58. DOI:10.1016/S2352-3026(22)00292-7 PUBMED:https://pubmed.ncbi.nlm.nih.gov/36370742

2. Du, X, et al., & Beach, CL (2018). Efficacy, safety and pharmacokinetics of subcutaneous azacitidine in Chinese patients with higher risk myelodysplastic syndromes: Results from a multicenter, single-arm, open-label phase 2 study. Asia-Pacific journal of clinical oncology 14(3) 270–278. DOI:10.1111/ajco.12835 PUBMED:https://pubmed.ncbi.nlm.nih.gov/29282890

3. DiNardo, CD, et al., & Pollyea, DA (2018). Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study. The Lancet. Oncology 19(2) 216–228. DOI:10.1016/S1470-2045(18)30010-X PUBMED:https://pubmed.ncbi.nlm.nih.gov/29339097

Revisions

• 06/2025 initial generated model